Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta
Status:
Completed
Trial end date:
2017-10-04
Target enrollment:
Participant gender:
Summary
Single-centre, double-blind, randomised, two-period, two-way crossover study to investigate
the pharmacokinetics and pharmacodynamics of RGB-02 as compared to Neulasta® administered as
a single subcutaneous injection in healthy adult subjects.